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Biomarkers of Peripheral Arterial Disease
John P. Cooke, MD, PHD,* Andrew M. Wilson, MBBS, PHD†
Stanford, California; and Victoria, Australia
Atherosclerotic arterial occlusive disease affecting the lower extremities is also known as peripheral artery dis-
ease (PAD). This disorder affects 8 to 12 million individuals in the U.S. and is increasingly prevalent in Europe
and Asia. Unfortunately, most patients are not diagnosed and are not optimally treated. A blood test for PAD, if
sufficiently sensitive and specific, would be expected to improve recognition and treatment of these individuals.
Even a biomarker panel of moderate sensitivity and specificity for PAD could refine risk stratification to select
individuals for diagnostic vascular examination. Alternatively, biomarkers for PAD may be useful in determining
prognosis, the risk for progression, or the response to therapy. Finally, the discovery of biomarkers associated
with PAD may provide novel insights into the pathophysiology of PAD and new therapeutic avenues to pursue.
Biomarkers may be derived from studies of the genome, transcriptome, proteome, or metabolome. The focus of
this review is on proteomic biomarkers associated with PAD. (J Am Coll Cardiol 2010;55:2017–23) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.090(
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phe prevalence of lower-extremity peripheral artery disease
PAD), assessed using the ankle-brachial blood pressure
ndex (ABI), has been estimated to be 10% to 20% in
ndividuals older than 65 years of age in community-based
tudies (1–4). Even greater prevalence is observed in indi-
iduals attending general medicine practices, in which 20%
o 30% of patients age 50 years and older have the disease
5,6). Peripheral arterial disease causes limb pain with exertion,
educes functional capacity and quality of life (7), and is
requently associated with coronary, cerebral, and renal artery
isease (8). Individuals with PAD are at increased risk for acute
ardiovascular events such as myocardial infarction, cerebro-
ascular attack, aortic aneurysm rupture, and vascular death, as
ell as ischemic ulceration and amputation (9,10). This in-
reased risk for cardiovascular morbidity and mortality is seen
ven in patients without symptoms (11).
Aggressive medical treatment of risk factors can substan-
ially reduce the mortality and morbidity of PAD (12).
nfortunately, PAD is underdiagnosed and undertreated,
ith most patients not receiving optimal management,
ncluding therapies proven to reduce mortality such as
ntiplatelet agents, statins, and converting enzyme inhibi-
ors (13). Suboptimal physician recognition and manage-
ent of the condition is in part because of poor public
wareness of PAD (14), inadequate training and tools for
rimary physicians, a lack of remuneration for screening
rom the *Division of Cardiovascular Medicine, Stanford University, Stanford,
alifornia; and the †Department of Medicine, University of Melbourne, Victoria,
ustralia. Drs. Cooke and Wilson are inventors on the patent that Stanford
niversity has filed for biomarkers for peripheral arterial disease. Dr. Cooke has
orked with Vermillion.l
Manuscript received May 17, 2009; revised manuscript received July 22, 2009,
ccepted August 16, 2009.15), and the absence of the classic symptom complex in a
ajority of the patients (16). Classical intermittent claudi-
ation (i.e., exertional leg discomfort relieved by rest) is only
oted by 10% to 30% of patients with PAD (7,13).
usculoskeletal disease or neuropathy commonly coexist
ith PAD and confound the clinical picture (7). Accord-
ngly, clinical assessment for PAD has a relatively poor
redictive value (10%) (17). Structured questionnaires
uch as the Edinburgh Claudication Questionnaire have
mproved sensitivity and specificity compared with clinician
ssessment (18), but these questionnaires only identify
atients with classical symptomatology. Because the current
ecognition of PAD is suboptimal, and because effective
herapy that improves mortality is available for these indi-
iduals, an efficacious strategy to screen the population for
AD is highly appealing.
AD: The Case for Screening
ompared with angiography, the ABI can detect hemody-
amically significant lesions with a sensitivity of 80% to 95%
nd a specificity of 95% to 100% (19,20). Furthermore, the
BI has independent prognostic value beyond the Framing-
am risk factors (21). The ABI is calculated from Doppler-
erived measurements of the systolic pressure at the brachial
nd ankle arteries. By convention, for each lower extremity,
he higher of the 2 ankle artery pressures is used for the ABI
alculation. The ABI for that extremity is the higher ankle
ressure divided by the higher of the 2 brachial artery
ressures.
Targeted screening with ABI is recommended by all
rofessional vascular societies, including the American Col-
ege of Cardiology (22). The American College of Cardi-
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Biomarkers for PAD? May 11, 2010:2017–23ology/American Heart Asso-
ciation guidelines support ABI
screening in high-risk patients
(defined as individuals age 50
years with diabetes and 1 other
atherosclerosis risk factor, those
age 50 to 69 years with a history
of smoking or diabetes, individ-
uals age 70 years, those with
leg symptoms with exertion or
ischemic rest pain, and those with
an abnormal lower-extremity pulse
examination) (22). Also, the
merican Diabetes Association recommends annual screening
or PAD in diabetics (23).
Despite the abundant evidence supporting the value of
he ABI, and despite careful studies that have revealed
uboptimal recognition of individuals with PAD and inad-
quate utilization of therapies that reduce mortality, there is
esistance to adopting the ABI as a screening tool. The U.S.
reventive Services Task Force has given the practice a “D”
evel recommendation (i.e., in their opinion, routinely pro-
iding the service to asymptomatic patients is ineffective or
arm from the test may outweigh benefits). Also, the
merican Academy of Family Physicians recommends
gainst the use of the test in asymptomatic persons (24).
These opinions are contrary to the recommendations of
ascular specialty societies and have been convincingly
ebutted (15). In brief, these unfortunate recommendations
re driven by the concern that screening may lead to
nnecessary tests and increased risk from subsequent inva-
ive studies or procedures. However, of much greater
oncern is the very real cost to the health care system and to
he patient of not identifying individuals with PAD. The
rimary purpose in screening for PAD is to identify indi-
iduals at high risk of vascular events (8,9,25–27) to target
hem for aggressive risk reduction interventions (28–33).
nfortunately, most patients with PAD are currently not
iagnosed and are not receiving therapies that can improve
heir prognosis (13,34).
eyond the ABI
mong vascular specialists, there is widespread recognition
f the value of the ABI and evidence-based documentation
f its sensitivity and specificity. However, a practical con-
ern is that most primary practitioners lack the specialized
quipment and trained personnel to perform ABI measure-
ents in the office setting. In the absence of an effective
creening strategy in the primary practitioner’s office, all
ndividuals at risk could be referred for a formal vascular
aboratory evaluation. This would be a costly screening
trategy.
The number of individuals that should be screened for
AD (i.e., all smokers who are50 years of age, all patients
Abbreviations
and Acronyms
ABI  ankle-brachial blood
pressure index
2M  2 microglobulin
CAD  coronary artery
disease
CRP  C-reactive protein
MD  mass spectroscopy
PAD  peripheral artery
diseaseith diabetes who are 50 years of age, and all individuals iho are 70 years of age) represents approximately 60
illion individuals in the U.S. An alternative screening
pproach would be to develop a blood biomarker, or panel
f biomarkers, that could stratify the risk for individuals in
he primary practitioner’s office. Such a panel could be
ssessed by a blood draw in the office and would optimally
dentify a smaller subset of patients for vascular evaluation.
uch an approach could reduce the overall cost of screening
hile improving recognition and proper management. This
lternative diagnostic paradigm requires progress toward
eveloping novel biomarkers of PAD.
hallenges in Discovering New Biomarkers
here are hurdles to the discovery of any new blood protein
iomarkers. The most daunting problem is the great diver-
ity of the proteome (i.e., plasma contains approximately
0,000 plasma proteins and even more protein fragments)
nd its dynamic range (approximately 10 orders of magni-
ude difference between the least and most abundant pro-
eins) (35). The discovery process is complicated by the fact
hat the 22 most abundant proteins, such as albumin and the
mmunoglobulins, constitute approximately 99% of the total
roteome mass (36). However, it is the low-abundance
roteins that are often of the greatest interest as novel
isease markers. Any technology to profile the plasma
roteome in an informative manner must be able to delve
eeply into the proteome and to discriminate differences in
he levels of low-abundance proteins. For example, cardiac
arkers such as troponin are found in the nanomolar range,
hereas cytokines are in the femtomolar range.
Another important issue is confounding by medications
r associated diseases. Careful phenotyping of the subjects is
ritical for proteomic discovery, and the control group
hould be matched for variables already known to influence
isease risk and outcome. Renal or hepatic disease may
nfluence the excretion or metabolism of a biomarker. Other
isorders may influence the level of a biomarker by patho-
hysiologic processes unrelated to the disease of interest
e.g., infection increases the plasma level of the cardiovas-
ular biomarker C-reactive protein [CRP]). Technical de-
ails such as how the blood is drawn, processed, and stored
an substantially affect the findings and lead to spurious
esults if the samples from different patient groups are not
reated similarly. For example, multiple freeze-thaws while
amples are studied cause protein degradation, introducing
rtifactual peaks in mass spectroscopic analyses.
Despite these challenges, the field of cardiovascular pro-
eomics continues to develop rapidly, and a range of
ollaborative initiatives have been undertaken. The National
nstitutes of Health/National Heart, Lung and Blood In-
titute has funded several centers for cardiovascular pro-
eomics (37). The Human Proteome Organization has re-
ently initiated a plasma proteome project (38). The early
hase of the project has reported the identification of approx-
mately 345 cardiovascular disease-related proteins in human
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May 11, 2010:2017–23 Biomarkers for PAD?lasma (39). However, until recently, there have been few
ttempts to detect biomarkers associated with PAD.
o Biomarkers of PAD Exist?
t could be argued that proteomic profiling is unlikely to
ield plasma biomarkers specific for peripheral, as opposed
o coronary, artery disease. This is because PAD and
oronary artery disease (CAD) share common cardiovascu-
ar risk factors and have many commonalities in pathophys-
ologic processes. A number of biomarkers have been
ssociated with PAD in population-based studies (Table 1)
40–61), such as inflammatory cytokines or chemokines,
arkers of endothelial dysfunction, mediators of angiogen-
sis or vascular regeneration, lipoproteins or lipid-associated
roteins, indicators of oxidative stress or ischemia-
eperfusion, metabolic modulators, and coagulation factors
40,50,52,53,62–64).
However, none of these biomarkers are specific for PAD
ecause they are elevated in CAD and other vascular
isorders. This is not surprising because these biomarkers
ere derived from “candidate protein”- based investigations
hat focused on proteins known to be associated with other
ascular diseases or with pathophysiologic mechanisms.
evertheless, it is quite likely that pathologic processes in
he peripheral circulation will lead to the release of PAD-
pecific biomarkers. This is because significant differences
xist throughout the vasculature in endothelial and vascular
mooth muscle gene expression (65,66). Preclinical studies
ave revealed functional differences as well; endothelium-
ependent vasodilation and smooth muscle vasoconstric-
ion, in response to a variety of agonists, differ in coronary
nd limb arteries (67). Similarly, in humans, endothelium-
ependent responses in the peripheral arteries are quite
ifferent than those in central arteries (68). These differ-
nces in vascular reactivity between the peripheral and
oronary arteries reflect differences in the expression of cell
urface receptors and signaling pathways. There are also
ell-established differences between vascular beds in the
xpression of endothelial chemokines and adhesion mole-
ules. These geographic differences are known to play a
hysiologic role in lymphocyte homing and other cellular
iomarkers Associated With PADTable 1 Biomarkers Associated With PAD
Inflammatory cytokines: CRP (40), interleukin-6 (41,42)
Markers of endothelial dysfunction: ADMA (43–46);
soluble cell adhesion molecules (47,48), Von Willebrand factor (49)
Modulators of angiogenesis: soluble Tie 2, VEGF (50);
hepatocyte growth factor (51)
Lipoproteins: oxidized LDL (52–54), lipoprotein(a) (55)
Indicators of oxidative stress: homocysteine (56),
8-hydroxy-2-deoxy-2-deoxyguanosine (57), isoprostanes (58)
Coagulation factors: thrombomodulin (59), D-dimer, TPA, PAI-1,
fibrinogen (60,61)
DMA  asymmetric dimethylarginine; CRP  C-reactive protein; LDL  low-density lipoprotein;p
AD peripheral artery disease; PAI plasminogen activator inhibitor; TPA tissue plasminogen
ctivator; VEGF  vascular endothelial growth factor.rafficking in immune surveillance (69). The phenotypic
ariation among vascular cells is a manifestation of their
xposure to disparate milieus, their developmental diver-
ence, and their persistent epigenetic differences (70,71).
We hypothesized that known and undiscovered pheno-
ypic differences between peripheral and coronary vascular
ells may affect their response to ischemia. Physiologists
ave long known that the stimulus of ischemia, followed by
eperfusion, causes characteristic changes in a microcircula-
ory bed, including the release of adhesion molecules and
roduction of inflammatory cytokines (72). We reasoned
hat chronic bouts of ischemia-reperfusion in the lower ex-
remity of the claudicant might induce the expression and
elease of proteins characteristic of the peripheral circulation.
pproach to Discovery
f Novel Biomarkers in PAD
ccordingly, we developed a discovery program for more
pecific biomarkers of PAD (73). Previous investigations of
iomarkers for PAD have used a “candidate protein”-based
pproach. By contrast, to discover PAD-specific biomark-
rs, we employed an “agnostic” approach, using plasma
roteomic profiling by mass spectroscopy (MS). We used a
ersion of MS known as surface-enhanced laser desorption
ime-of-flight MS. The advantage of this version is that it
rovides for a rapid chip-based segregation of peptides
ased on charge and lipophilicity. When combined with pH
ractionation, the technique enhances MS resolution of the
housands of plasma proteins. Proteins in the sample are
ound to the chip. An energy-absorbing matrix is applied,
edissolving the proteins on the chip, allowing the proteins
o cocrystallize with the matrix as it dries. Laser excitation
onizes the matrix, causing it to release the proteins into the
ight tube of a mass spectrometer; the proteins subsequently
trike a detector at the end of the tube. The resulting signal
rovides data from which the molecular weight and amount
f the peptide can be assessed. The comparison of the
pectra from cases and controls can lead to the identification
f a peak that is different between the groups. This peak
epresents a protein that may be a new biomarker. Subse-
uent studies using complementary methods (MS-MS,
mmunoaffinity columns, enzyme-linked immunosorbent
ssay, Western analysis) are completed to confirm the
dentity of the protein.
We performed comprehensive proteomic profiling using
his method in 88 patients with or without PAD. Our
tudies revealed several MS peaks that were increased in
AD cases. Based upon its molecular weight, one of these
eaks was thought to be 2 microglobulin (2M). We chose
his protein to study further as a proof of concept (73). In a
onfirmatory study using other proteomic approaches (i.e.,
estern analysis and immunoaffinity studies), we found
2M to be elevated in subjects with PAD (and its plasma
evels were inversely correlated with treadmill exercise ca-
acity). Finally, we validated this biomarker using a neph-
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Biomarkers for PAD? May 11, 2010:2017–23lometric assay in a cross-sectional case-control study of
atients undergoing elective coronary angiography for a
iagnosis of CAD. We chose our cases and controls so that
onfounding clinical covariates would contribute minimally
Figure 1 Odds Ratio of CAD  PAD Status by
AHA Risk Score and by Biomarker Panel Score
There is a positive interaction between the 2 assessments of disease risk. Individ-
uals were assigned an AHA risk score using the traditional cardiovascular risk fac-
tors as described (19). AHA risk scores of 5 (low), 5 to 10 (medium), and 10
(high) were associated with increasing risk of PAD (p  0.006 for men and p 
0.001 for women using the score from the linear regression by analysis of vari-
ance). The tertile cutoffs of the biomarker panel score were used to determine the
risk level: low (0.991), medium (0.991 to 1.033), and high (1.033). AHA 
American Heart Association; CAD  cardiac artery disease; n.s.  not significant;
PAD  peripheral artery disease.
Figure 2 ROC Analysis Using Risk Factors
 Biomarkers for PAD Diagnosis
Receiver-operating characteristic (ROC) analysis of conventional risk factors, the
biomarker panel score, and a combination of conventional risk factors and the
biomarker panel score. DM  diabetes mellitus; PAD  peripheral artery disease.o the difference between the 2 phenotypes. Cases had
emodynamically significant PAD as documented by re-
uced ABIs, whereas controls had normal ABIs. This study
alidated 2M as a biomarker associated with PAD, inde-
endently of other cardiovascular risk factors.
iomarker Panels
or any single biomarker (such as CRP), a certain percent-
ge of subjects with abnormal levels will not have disease
false positives), whereas those with disease may have
ormal levels (false negatives). One approach to addressing
his problem is to use a panel, in which each of the
iomarkers contributes independent diagnostic information.
iomarker “panels” and index scores are beginning to be
sed in medicine to refine diagnosis and to aid in prognos-
ication. For example, such index scores incorporating novel
iomarkers have been used to predict clinical outcomes in
epatocellular and breast malignancies (74,75). Recently,
ang et al. (76) combined multiple biomarkers from the
ramingham study to predict cardiovascular outcomes and
eath.
In our discovery study, an additional biomarker candidate
dentified was cystatin C. A subsequent study of 540
igh-risk individuals revealed that 2M, cystatin C, high-
ensitivity CRP, and glucose were associated with PAD
ndependently of the traditional risk factors of age, diabetes
ellitus, hyperlipidemia, hypertension, and tobacco use.
mong the plasma markers tested, 2M and cystatin C had
he highest correlation with ABI, higher than any of the
Figure 3 Biomarker Panel for PAD
The optimal PAD blood test is likely to be composed of a panel of biomarkers
that circulate systemically but which reflect the activity of local pathophysio-
logic processes contributing to inflammation, oxidative stress, matrix remodel-
ing, endothelial dysfunction, coagulation, metabolic perturbations, and
ischemia-reperfusion. Unique characteristics of the peripheral circulation may
provide for specificity of the biomarkers that are released. In brackets are
biomarkers that are elevated in PAD but which are not specific. The identifica-
tion of novel and specific biomarkers is underway (48–51,54–61,79–89).
ADMA  asymmetric dimethylarginine; B2M  2 microglobulin; EPC  endothe-
lial progenitor cell; glu  glucose; IL  interleukin; I/R  ischemia-reperfusion;
Lp(a)  lipoprotein (a); MCP  monocyte chemotactic protein; MMP  matrix met-
alloproteinase; PAD  peripheral artery disease; sRAGE  soluble receptor for
advanced glycosylation end products; sVCAM  soluble vascular cell adhesion
molecule; TF  tissue factor; VEGF  vascular endothelial growth factor.
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May 11, 2010:2017–23 Biomarkers for PAD?onventional risk factors of age, smoking status, and diabe-
es status. A biomarker panel score derived from 2M,
ystatin C, high-sensitivity CRP, and glucose had an
ncreased association with PAD status (77), independently
f the traditional risk factors (Fig. 1).
This biomarker panel is independent of, but only adds
odestly to, the information provided by the Framingham
isk factors (Fig. 2). Although it is an imperfect prototype,
his panel provides proof of concept for the promise of a
ultimarker approach. Of note, a recent prospective cohort
tudy of 1,000 ambulatory elderly Japanese subjects for 8
ears revealed that 2M, cystatin C, and CRP were inde-
endent predictors of mortality (78). The most informative
iomarker was 2M. The area under the receiver operating
haracteristic curve for 8-year mortality was greatest for
2M (0.70; 95% confidence interval [CI]: 0.66 to 0.74),
ollowed by cystatin C (0.66; 95% CI: 0.62 to 0.70) and
RP (0.57; 95% CI: 0.53 to 0.61). The authors concluded
hat serum 2M is an independent predictor of total
ortality in a general population of older adults and may be
better predictor than cystatin C or CRP.
onclusions
here is a strong clinical need for more specific biomarkers
or PAD. A blood test for PAD would increase recognition
f the disease and thereby improve clinical care. It is likely
hat a biomarker panel with high sensitivity and high
pecificity for PAD will be composed of biomarkers that
irculate systemically but reflect the activity of local patho-
hysiologic processes (Fig. 3) (79–89). To be clinically
seful, the optimal biomarker(s) should be stable and easily
easured and should provide diagnostic or prognostic
nformation that is incremental to existing biomarkers
Table 2). The search for proteomic biomarkers is currently
eing driven by rapid advances in technology and bioinfor-
atics that facilitate high-throughput analysis of blood
rom clinical studies with sufficient sample sizes. The
pplication of these technologies to PAD should be encour-
ged because they are likely to yield useful diagnostics for
AD, as well as novel insights into the pathophysiology of
eatures of an “Ideal” PAD BiomarkerTable 2 Features of an “Ideal” PAD Biomarker
Sensitive for the presence of disease
Specific, good negative predictive value
Correlates with prognosis
Measurable with high-throughput techniques
Correlates with disease-specific features: ABI, walking time
Levels minimally or predictably affected by confounding factors
Reproducible
Cost effective
Acceptable to patients and clinicians
Complementary to current strategies
BI  ankle-brachial blood pressure index; PAD  peripheral artery disease.he disease.eprint requests and correspondence: Dr. John P. Cooke,
tanford University School of Medicine, Division of Cardiovas-
ular Medicine, 300 Pasteur Drive, Falk Cardiovascular Research
enter, Stanford, California 94305-5406. E-mail: john.cooke@
tanford.edu.
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